MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2
Affiliations
Osteosarcoma patients with lung metastasis and local invasion remain challenging to treat despite the significant contribution of the combination of surgery and neo-adjuvant chemotherapy. Our previous microarray study demonstrated that miR-302b had significantly lower expression in osteosarcoma cell lines than in osteoblast cell lines. In the present study, we further elucidated the role of miR-302b in regulating the migration and invasiveness of osteosarcoma. MiR-302b expression was markedly down-regulated in osteosarcoma cell lines and clinical tumour tissues. Lower levels of miR-302b expression were significantly associated with metastasis and high pathological grades. A functional study demonstrated that over-expression of miR-302b suppressed tumour cell proliferation, invasion and migration in vitro and in vivo. Runx2 was identified as a direct target gene for miR-302b by bioinformatics analysis and dual-luciferase reporter gene assay. Moreover, over-expression of miR-302b induced down-regulation of Runx2, OPN, MMP-2, MMP-9, MMP-12, MMP-14, and VEGF in 143B cells. Exogenous expression of Runx2 partially rescued the inhibitory effect of miR-302b on the invasion and migration activity of 143B osteosarcoma cells. Taken together, our results indicate that miR-302b functions as a tumour repressor in the invasion and migration of osteosarcoma by directly downregulating Runx2 expression and may be a potential therapeutic target for osteosarcoma.
Miyamoto T, Fukase N, Kawamoto T, Fujiwara S, Hara H, Sawada R Oncol Rep. 2024; 53(2).
PMID: 39704263 PMC: 11667212. DOI: 10.3892/or.2024.8857.
Leonardi L, Manuali E, Bufalari A, Porcellato I Front Vet Sci. 2024; 11:1292852.
PMID: 38362297 PMC: 10867244. DOI: 10.3389/fvets.2024.1292852.
Todosenko N, Khlusov I, Yurova K, Khaziakhmatova O, Litvinova L Int J Mol Sci. 2023; 24(10).
PMID: 37240338 PMC: 10219319. DOI: 10.3390/ijms24108993.
Research progress on microRNA in gout.
Xie J, He C, Su Y, Ding Y, Zhu X, Xu Y Front Pharmacol. 2022; 13:981799.
PMID: 36339582 PMC: 9631428. DOI: 10.3389/fphar.2022.981799.
Cheng S, Wang W J Bone Miner Metab. 2022; 40(4):554-560.
PMID: 35639175 DOI: 10.1007/s00774-022-01319-5.